Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 119.15 is 63% below its estimated 1-year average of 323.13, near the low end of its estimated 1-year range (119.15–389.99).
As of 2026-10-06T14:16:14.202Z.
Calculation as of: 2026-10-06T14:16:14.202Z.
Quote observation: 2026-10-06T14:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
119.15
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.04
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
+2849.26%
vs the sector median at left
Canton Strategic Holdings Inc
Market Cap
$178.23M
PS Ratio
119.15
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.51M
PS Ratio
N/A
TTM Avg
344.10
3Y Avg
344.10
5Y Avg
344.10
Market Cap
$170.58M
PS Ratio
3.79
TTM Avg
34.48
3Y Avg
14.27
5Y Avg
9.83
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $178.23M | 119.15 | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $173.51M | N/A | 344.10 | 344.10 | 344.10 |
| Journey Medical Corporation (DERM)vs › | $181.64M | 2.66 | 2.93 | 2.14 | 1.57 |
| Cue Biopharma, Inc. (CUE)vs › | $175.98M | 4.67 | 4.86 | 10.20 | 38.22 |
| Precision BioSciences, Inc. (DTIL)vs › | $170.58M | 3.79 | 34.48 | 14.27 | 9.83 |
| MediWound Ltd. (MDWD)vs › | $172.45M | 14.54 | 12.04 | 9.32 | 6.72 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.07M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $191.04M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | 3.18 | 3.40 | 1.68 | 2.05 |
| Inogen, Inc. (INGN)vs › | $159.88M | 0.45 | 0.50 | 0.55 | 0.91 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $1,495,859 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $1,495,859 |
Current P/S: $178,230,291 market capitalization ÷ $1,495,859 TTM revenue = 119.15x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:15:22.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 119.15, P/S is at an extreme level, where the multiple carries little signal — higher than 0% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
291.40
median
323.30
estimated 1-year high
389.99
P/S Ratio
119.15
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 337.80 |
| 2026-10-02 | 326.20 |
| 2026-10-01 | 317.50 |
| 2026-09-30 | 345.04 |
| 2026-09-29 | 345.04 |
| 2026-09-28 | 389.99 |
| 2026-09-25 | 372.59 |
| 2026-09-24 | 334.90 |
| 2026-09-23 | 324.75 |
| 2026-09-22 | 355.19 |
| 2026-09-21 | 353.74 |
| 2026-09-18 | 333.45 |
| 2026-09-17 | 304.45 |
| 2026-09-16 | 295.75 |
| 2026-09-15 | 297.20 |
| 2026-09-14 | 304.45 |
| 2026-09-11 | 305.90 |
| 2026-09-10 | 311.70 |
| 2026-09-09 | 320.40 |
| 2026-09-08 | 323.30 |
| 2026-09-04 | 330.55 |
| 2026-09-03 | 326.20 |
| 2026-09-02 | 301.55 |
| 2026-09-01 | 330.55 |
| 2026-08-31 | 330.55 |
| 2026-08-28 | 321.85 |
| 2026-08-27 | 340.70 |
| 2026-08-26 | 323.30 |
| 2026-08-25 | 334.90 |
| 2026-08-24 | 310.25 |
| 2026-08-21 | 317.50 |
| 2026-08-20 | 320.40 |
| 2026-08-19 | 303.00 |
| 2026-08-18 | 291.40 |
| 2026-08-17 | 294.30 |